Back in September, Orexigen Therapeutics Inc.'s CEO told BioWorld Today that the firm hoped to avoid a near-term financing by securing an ex-U.S. partnership to help offset costs for the large cardiovascular outcomes trial (CVOT) required by the FDA to get obesity candidate Contrave (naltrexone HCl/buproprion) over the finish line.